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ABSTRACT 
Dengue viruses cause the most important human 
viral disease transmitted by mosquitoes. In recent 
years, a great deal has been learned about 
molecular details of dengue virus genome 
replication; however, little is known about genome 
encapsidation and the functions of the viral 
capsid protein. During infection, dengue virus 
capsid progressively accumulates around lipid 
droplets by an unknown mechanism. Here, we 
examined the process by which the viral capsid is 
transported from the ER membrane, where the 
protein is synthesized, to lipid droplets. Using 
different methods of intervention, we found that 
the GBF1-Arf1/Arf4-COPI pathway is necessary for 
capsid transport to lipid droplets, while the 
process is independent of both COPII 
components and Golgi integrity. The transport 
was sensitive to brefeldin A, while a drug resistant 
form of GBF1 was sufficient to restore capsid 
subcellular distribution in infected cells. The 
mechanism by which lipid droplets gain or lose 
proteins is still an open question. Our results 
support a model in which the virus uses a non-
canonical function of the COPI system for capsid 
accumulation on lipid droplets, providing new 
ideas for antiviral strategies.  
INTRODUCTION  
Dengue virus (DENV) is considered one of the most 
important arthropod-borne human pathogen 
worldwide. This virus is a member of the Flavivirus 
genus in the Flaviviridae family together with other 
important pathogens such as yellow fever virus (YFV), 
West Nile virus (WNV), Saint Luis encephalitis virus 
(SLEV), and Japanese encephalitis virus (JEV). 
DENV alone causes about 390 million infections per 
year. Despite this large public health problem and the 
urgent need to control DENV infections, vaccines and 
specific antivirals are still unavailable.  
DENV, like other plus strand RNA viruses, induces a 
profound rearrangement of cellular membranes to 
provide platforms for viral replication (1-3). DENV 
RNA synthesis occurs in membranous structures 
called vesicle packets that function as viral genome 
factories, which are in close association to viral 
particle morphogenesis in the ER membrane (3). 
During this process, the viral capsid protein (C) is 
responsible for recruiting the viral genome during viral 
encapsidation, forming a nucleocapsid that buds into 
the ER lumen, acquiring membranes and the 
structural proteins E and prM (4, 5). The new viral 
particle travels through the secretory pathway to be 
released by exocytosis. 
The viral C is a small, highly basic protein that forms 
homodimers in solution (6, 7). We have previously 
shown that C progressively accumulates around 
cellular lipid droplets (LDs) during DENV infection (8).  
Atomic force microscopy has been recently used to 
define biochemical properties of this C-LD interaction 
(9). LDs are dynamic organelles involved in lipid 
metabolism that regulate storage and turnover of 
neutral lipids. They contain mostly triacylglycerols and 
sterol esters surrounded by a phospholipid 
monolayer, decorated with proteins (10-12). Previous 
studies using leukocytes have demonstrated an 
increased amount of LDs per cell in samples from 
patients with dengue hemorrhagic fever when 
compared with that from healthy volunteers (13). 
Similar observations were reported in DENV infected 
human macrophages and in different infected cell 
lines, such as A549, Hep-G2 and BHK (8, 13-15). 
Interestingly, it has been shown that DENV infection 
triggers the redistribution of the rate-limiting enzyme 
in lipid biosynthesis, the fatty acid synthesize (FASN) 
to the ER. It has been demonstrated that binding of 
FASN to the viral protein NS3 increases cellular fatty 
acid synthesis (16); and that pharmacological 
inhibition of FASN activity blocks induction of LDs 
during DENV infection (8). A relationship between 
autophagy-mediated lipid droplet degradation and 
DENV infection has been also observed (17). It has 
been suggested that lipid degradation was necessary 
during DENV RNA synthesis. However, inhibition of 
autophagy appears to affect different stages of viral 
infection. In this regard, destabilization of beclin-
Vps34-Atg14, which inhibits autophagy, was shown to 
have a modest effect on viral RNA synthesis but a 
profound effect on particle infectivity, due to defects 
on peptide pr release from prM during particle 
maturation (18). Thus, it is likely that lipid biosynthesis 
and degradation are both necessary during different 
stages of the viral life cycle. More recently, the Ras-
related protein in brain (Rab), GTPase Rab18, which 
participates in lipid exchange between ER and LD 
compartments, was shown to be necessary for 
efficient DENV replication and to have a positive role 
in LD induction (15). Even though different lines of 
evidence link DENV infection to LD metabolism, the 
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functional significance and the mechanisms by which 
the virus manipulates LDs remain obscure. We have 
previously reported that C accumulation on LDs is 
necessary for efficient viral particle production; but the 
role of LDs in this process is still unknown. Budding 
viral particles in the ER have been observed next to 
the pores of vesicle packets, where the viral genome 
is replicated, suggesting that LDs are not the place of 
genome recruitment during encapsidation (3). It is 
possible that accumulation of C on LDs modulates the 
host lipid metabolism required for viral particle 
formation or serves as storage of the viral protein in 
early stages of viral replication (8). 
To further examine the function of C on LDs and 
explore new tools for antiviral intervention, we 
investigated the process by which C is transported 
from the ER membrane to LDs during DENV infection. 
How LDs receive or deliver proteins is still an open 
question. In recent years, more than 200 cellular 
proteins have been reported that associate to LDs; 
including lipid metabolism enzymes, Rab GTPases, 
SNARE proteins and coatomer components (12). The 
most prominent lipid droplet associated proteins are 
the PAT proteins (Perilipin, Adipofilin/ADRP, and the 
Tail interacting protein/TIP47) (19). Interestingly, a 
function of components of the vesicle trafficking 
systems, Coat Protein II and I (COPII and COPI), has 
been reported for the transport of different cellular 
proteins to LDs (20-22). Normally COPII vesicles 
mediate transport of proteins and lipids from the ER to 
Golgi, while COPI mainly participate in the retrieval of 
proteins from the Golgi back to the ER.  How COP 
components mediate delivery of proteins to LDs is 
unclear, but might involve novel functions of this class 
of proteins. Here, we investigated the involvement of 
these host factors in the accumulation of C on LDs. 
Because DENV requires an active vesicle transport 
system for viral maturation and egress, we restricted 
our studies to evaluate the C transport in a single viral 
replication cycle. Using different methods of 
intervention, we defined that C association to LDs 
requires a functional GBF1 protein. The process was 
found to be COPI dependent, COPII independent and 
did not involve the Golgi complex, supporting a non-
canonical function of this cellular transport system. 
We believe that dissecting the host machinery used 
during DENV infection will provide novel ideas for 
employing host targets for antiviral approaches. 
 
RESULTS  
Delivery of capsid to LDs is BFA sensitive  
It has been previously reported that the DENV C 
protein associates to different cellular compartments 
during viral infection (8, 23, 24). Using 
immunofluorescence assays and subcellular 
fractionation of DENV infected cells, we observed C in 
the nucleus and cytoplasm (Fig. 1A and 1B). During 
viral infection, C is translated as a polyprotein 
associated to ER membranes and it is proteolytically 
processed to release the mature protein. Mature C 
was detected by western blot at 12, 16 and 20 h post 
infection in membrane, cytoplasmic and nuclear 
fractions (Fig. 1B).  Immunofluorescence studies 
showed that the cytoplasmic C partially co-localized 
with the host protein TIP-47 and the viral E protein, 
which associate to LDs and ER, respectively (Fig. 
1A). In the nucleus, C co-localized with the nucleolar 
B23 protein (Fig. 1A). Visualization of proteins on LDs 
is limited when methanol is used as fixation method 
due to extraction of lipids (25). Because 
paraformaldehyde (PFA) preserves the integrity of 
LDs, this method was elected for detection of proteins 
on LDs (Fig. 1B). We conclude that in DENV infected 
cells, C accumulates in nucleolus, LDs and ER 
membranes.  
The mechanism by which host proteins are 
transported to LDs is still not fully understood. It is 
possible that C directly associates to nascent droplets 
after proteolytic processing or, alternatively, uses a 
specific transport system. In this regard, recent 
reports have implicated components of COPII and 
COPI complexes in the transport of some cellular 
proteins to LDs (20, 22). It has been shown that COPI 
and COPII are necessary for ADRP and ATGL 
accumulation on LDs, and this process was sensitive 
to brefeldin A (BFA), a GTP exchange factor inhibitor 
that blocks COPI activity. In contrast, other proteins 
such as TIP47, were found to be independent of COPI 
and COPII systems (20, 22). Thus, we examined the 
requirement of host proteins for C accumulation on 
LDs in DENV infected cells. Because BFA was 
reported to inhibit ADRP and ATGL accumulation on 
LDs, we first evaluated C distribution in cells treated 
or not with this drug. It is important to clarify that 
DENV particle morphogenesis and release requires a 
functional secretory pathway (26); and it has been 
demonstrated that BFA inhibits viral particle secretion 
(27). Therefore, to avoid new rounds of infections that 
would be sensitive to BFA, we examined the impact of 
the drug on C subcellular distribution in a single round 
of infection. To this end, cells were treated with 
different concentrations of BFA at 8h post-infection 
and pre-treated with oleate to promote formation of 
LDs. The correlation coefficient of C with a LD marker 
was drastically reduced in the presence of BFA, while 
no effect on C accumulation in nucleolus was 
observed (Fig. 2A and 2B). The total amount of 
mature C detected in cells treated or not with BFA 
was similar as determined by western blot (Fig. 2C), 
indicating that BFA did not affect viral translation or 
RNA amplification in the conditions used. The effect of 
different concentrations of drug indicated that 
concentrations as low as 0.05 g/ml greatly reduced 
C on LDs (Fig. 2D). Moreover, the effect was found to 
be reversible. Localization of C on LDs was recovered 
2h after incubation of cells in media without BFA (Fig. 
2E).  The results indicate that BFA did not significantly 
change the total amount of C neither the nucleolar 
accumulation of the viral protein in infected cells; 
however, it greatly reduced protein association to 
LDs.  
BFA inhibits several GTP exchange factors (GBF1, 
BIG1 and BIG2). Because golgicide A (GCA) has 
been shown to be more specific for GBF1 inhibition, 
which is the GEF involved in the Arf1-COPI pathway 
(28), the effect of GCA on C association to LDs was 
also examined. GCA greatly reduced C accumulation 
on LDs (Fig. 2F), suggesting that transport of C to 
LDs is sensitive to GBF1 inhibition. 
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In these studies we could not evaluate the impact of 
the lack of C association to LDs by BFA on viral 
particle production because the drug inhibits viral 
particle secretion independently of C (27). 
Accordingly, BFA greatly decreased viral titers in our 
experimental conditions (Fig. S1).  
Disruption of the Golgi complex does not alter 
capsid localization on LDs 
Inhibition of GBF1 and COPI functions produces 
alterations in the secretory pathway, including Golgi 
disassembly, phenotype observed in the presence of 
BFA (22, 29). To examine whether the BFA effect on 
C distribution was the result of a general alteration on 
the host vesicular transport system, a dominant 
negative form of Rab1b was used. This protein is a 
GTPase that plays a role in ER to Golgi transport (30). 
It has been previously demonstrated that a dominant 
negative form of Rab1b causes Golgi reabsorption 
into the ER, analogous to that described for BFA 
treatment (29). Thus, we expressed wild type or 
dominant negative Rab1b (N121I) protein fused to 
GFP in DENV infected cells and evaluated C 
association to LDs. As a control for function of the 
dominant negative protein, localization of giantin, a 
Golgi associated protein, was examined. N121I 
Rab1b was mainly cytosolic and induced rapid Golgi 
disruption as observed by giantin redistribution (Fig. 
3A), but did not alter C association to LDs (Fig. 3B). 
Cells expressing Rab1b-GFP displayed the typical 
ring-like structures of C on LDs (Fig. 3B). The results 
suggest that components of the ER-Golgi machinery 
are involved in C localization on LDs, independently of 
Rab1b activity and Golgi integrity but sensitive to 
BFA. 
Capsid accumulation on LDs requires COPI 
components but is independent of COPII function 
COPI and COPII systems have been implicated in the 
transport of host proteins to LDs (20-22, 31); 
therefore, we analysed the requirement of 
components of these systems on C transport to LDs 
during DENV infection. We used siRNAs directed to 
different subunits of COPI and COPII in A549 cells. 
Cells were transfected with siRNAs specific for COP 
subunit (COPI component), Sec13 (COPII 
component) or nonrelated control siRNAs, and then 
infected with DENV (Fig. 4A). Depletion of COP was 
about 70% and showed a drastic effect on C 
association to LDs without altering TIP47 localization 
(used as control). In contrast, depletion of Sec13 did 
not alter the amount of C nor its association to LDs, 
which remained co-localized with TIP47 (Fig. 4A and 
4B). The results suggest that C transport to LDs in 
infected cells depends on COPI but is independent of 
COPII components.  
The possible involvement of COPI on C association to 
LDs lead us to analyze a function of Arf1 in this 
process. To study this possibility, we evaluated the 
depletion of Arf1 on C distribution in DENV infections. 
Depletion of Arf1 in infected A549 cells was almost 
complete, while C and TIP47 remained associated to 
LDs (Fig. 4D and 4E). This result was unexpected 
because Arf1 activity is proposed to be necessary for 
COPI recruitment. It is possible that COPI is directly 
recruited by GBF1, without Arf1 requirement (32). 
Alternatively, other Arf isoforms could participate in 
this process. Kahn and colleagues have previously 
reported a redundancy of Arf functions in the cell (33). 
Therefore, we analyzed depletion of different Arfs and 
found that simultaneous knock down of Arf1 and Arf4 
largely reduced C transport to LDs, while cells lacking 
only Arf4 did not affect C subcellular distribution (Fig. 
4D and 4E). These studies support the idea that 
localization of C on LDs requires recruitment of COPI 
by either Arf1 or Arf4. 
BFA resistant GBF1 restores capsid delivery to 
LDs in DENV infected cells 
To further examine the role of GBF1 on C association 
to LDs different methods were used. First, the effect 
of expressing a WT or a dominant negative form of 
GBF1 (E794K) was evaluated. A549 cells were 
infected with DENV and then transfected with 
expression constructs encoding GBF1 fused to YFP 
(Fig. 5A).  While expression of the WT protein did not 
affect C association to LD, the E794K inactive protein 
reduced about 70% the amount of cells with C on LDs 
(Fig. 5A), suggesting the requirement of an active 
GBF1 protein. To confirm this observation, the effect 
of RNAi mediated depletion of GBF1 on C localization 
was also tested. The efficiency of GBF1 depletion was 
observed by western blots (Fig. 5B). 
Immunofluorescence analysis using antibodies to 
detect both GBF1 and C indicated that infected cells 
lacking GBF1 (without green signal in Fig. 5B) also 
lacked C localization on LDs, while cells expressing 
detectable levels of endogenous GBF1 showed a 
clear association of C to LDs. 
Taken together, it is likely that BFA inhibition of GBF1 
is responsible for the phenotype observed. Thus, we 
examined whether a GBF1 mutant that is resistant to 
BFA was able to reverse the effect of the drug. Cells 
were transfected with plasmids expressing YFP alone, 
GBF1-WT or BFA-resistant GBF1 (M832L) fused to 
YFP, and then infected with DENV in the presence or 
absence of BFA (Fig. 6A). In the absence of BFA, 
between 90 to 95% of the cells that expressed YFP 
showed C on LDs, whether they were transfected with 
the control plasmid or either GBF1 constructs, 
suggesting that GBF1 overexpression had no effect 
on C localization (Fig. 6B). In the presence of BFA, 
the amount of cells expressing YFP control with C on 
LDs was reduced to 18%, whereas it was about 40% 
and 80% in WT or M832L GBF1 expressing cells (Fig. 
6B). It was evident that cells expressing or not the 
BFA resistant form of GBF1 showed a remarkable 
difference on C distribution in the presence of drug 
(Fig. 6A). The results indicate that a BFA resistant 
form of GBF1 was sufficient to revert the effect of the 
drug, confirming the requirement of an active GBF1 
for C subcellular distribution during DENV infection.   
DISCUSSION 
Different lines of evidence support a link between 
DENV replication and LD metabolism. Thus, it is 
important to further understand why and how the virus 
manipulates LDs. Here, we examined the requirement 
of host factors for C accumulation around LDs during 
infection with the final goal of identifying possible 
antiviral targets. We defined that an active GBF1-Arf-
4 
 
COPI pathway is necessary for C transport from the 
ER to LDs in human infected cells.  The process was 
found to be dependent of COPI but independent of 
Golgi integrity, supporting a non-canonical function of 
components of this vesicle transport system.  
During DENV infection C distributes between different 
cellular compartments:  nucleolus, LDs and ER 
membranes. This distribution is observed early after 
infection, suggesting that it is not a consequence of 
cell damage during viral replication (Fig. 1). In the viral 
polyprotein, C is followed by an anchor peptide that 
directs prM-E to the ER lumen. It has been shown that 
the anchor peptide is not necessary for C 
accumulation on LDs (8). Release of C by the viral 
NS2B3 cleaves the anchor peptide rendering a 
mature protein that remains attached to the 
cytoplasmic side of the ER membrane (34), and then 
it is transported to LDs and nucleus. Why the protein 
accumulates in these cellular compartments is still 
unknown. We have previously shown that C could be 
toxic for viral RNA synthesis due to its high affinity for 
nucleic acids. In this regard, it is possible that C is 
sequestered in different organelles early during 
infection to avoid premature interaction with the viral 
RNA. However, more studies are necessary to define 
mechanistic aspects of C functions in the nucleus and 
LDs. 
Previous studies using genome wide RNAi screens in 
drosophila, have linked COPI components with LD 
metabolism and composition (21, 22). It has been 
shown that COPI regulate lipid homeostasis, likely by 
promoting transport of enzymes, like ATGL, to the 
surface of LDs (22). Here, we used different methods 
to evaluate the involvement of components of this 
trafficking system on C transport. Because depletion 
or inhibition of these components could alter the 
composition and abundance of LDs, the experiments 
were performed in cells pretreated with oleate. Our 
results support the idea that an active GBF1 
participates in the transport of C to LDs (Fig. 5 and 6). 
It is possible that the cellular protein accumulates on 
viral induced membranes and activates Arf1 and/or 
Arf4 to recruit COPI (Fig. 4). Depletion of COPI 
subunits reduced transport of C to LDs, while 
depletion of Sec13 of COPII did not alter C distribution 
in DENV infected cells (Fig. 4). Therefore, it is unlikely 
that C is first transported to a cis-Golgi compartment 
before it is directed to LDs. In this regard, a dominant 
negative form of Rab1b that induces Golgi disruption 
did not affect C subcellular distribution. We also 
observed that BFA greatly reduced C accumulation on 
LDs while it did not alter its transport to the nucleolus 
(Fig. 2). The effect of BFA was reversible by drug 
removal and its specificity on GBF1 was 
demonstrated by the recovery of C on LDs in the 
presence of a BFA resistant form of GBF1 (Fig 6). We 
propose that COPI/Arf/GBF1 system mediate 
transport of C from the place where it is synthesized 
on the ER membranes to LDs, independently of Golgi 
integrity. 
The best described function of COPI vesicles is to 
mediate retrograde vesicle transport between Golgi 
cisternaes and from the Golgi to the ER, while COPII 
mediates anterograde transport mainly from the ER; 
however, it is evident that the canonical vesicular 
transport of cargo, as occurs in the secretory 
pathway, is not possible for protein transport to LDs. 
The monolayer of phospholipids that constitute the LD 
surface cannot fuse to a typical bilayer of a coated 
vesicle. Different possibilities that explain the 
transport of proteins have been suggested. For 
instance, lateral movement of proteins from ERES/ 
ERGIC sites to LDs, or loading of nascent droplets of 
specific proteins (20, 35). A very recent report showed 
that cells lacking Arf1 and COPI have an increased 
amount of phospholipids on LDs, resulting in 
decreased LD surface tension and impairment to form 
bridges with the ER (36). Based on these recent 
findings, modulation of ER-LD membrane bridges, 
without including vesicle formation, was proposed as 
a new mechanism for controlling protein transport 
from the ER to LDs (36). Our results are in agreement 
with this model, supporting the idea that C is 
transported from the ER to LDs using new functions of 
COPI. 
An emerging theme in pathogen biology is the 
interaction of bacteria, viruses, and protozoan with 
LDs (37-39). The mechanism by which these 
pathogens co-opt LDs remains to be elucidated. In the 
case of viruses, a link between hepatitis C virus 
(HCV) replication and LDs has been extensively 
documented (40-42). During HCV infection, the core 
protein, as well as other viral proteins, accumulates 
on the surface of LDs (43-45). This localization of core 
has been proposed to play an important role in viral 
encapsidation (40, 42, 44-49). Interestingly, a recent 
study analyzing the trafficking of core during HCV 
infection suggested that BFA treatment increase the 
amount of the protein on LDs (50). Thus, DENV C and 
HCV core appear to use distinct mechanisms for LD 
association, one sensitive and the other one resistant 
to BFA, respectively. Taking into account previous 
studies,  there are at least two different pathways 
involved in delivering proteins to LDs, one dependent 
on COPI (and COPII in some cases), sensitive to BFA 
(such as ADRP, ATGL and DENV C); and the other 
one independent on these trafficking systems and 
resistant to BFA (such as TIP47 and possibly HCV 
core).   
Different viruses subvert the GBF1/Arf/COPI system 
during infection. In several cases, components of this 
pathway are involved in non-canonical functions such 
as the case of GBF1 on picornavirus replication (51-
54) and GBF1-Arf1 in Ebola virion formation (55). 
Here, we found that DENV uses this host trafficking 
system for C accumulation on LDs. Because the role 
of GBF1/Arf/COPI on LD protein transport is just 
emerging as a novel function of these proteins, further 
studies using different viruses that co-op LDs will help 
to uncover details of this cellular process and 
hopefully provide new ideas for antiviral approaches. 
 
MATERIALS AND METHODS 
Cells and viruses 
A549 human epithelial lung cells were cultured in 
Dulbecco’s modified Eagle’s medium F-12 (Ham) 
supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. Stocks of 
DENV-2 16681 were prepared in mosquito cells 
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(C6/36) and used to infect A549, as previously 
described (56).  
Antibodies and immunofluorescence assays  
For immunofluorescence and Western blot assays the 
following antibodies were used: mouse monoclonal 
anti-B23 (Abcam), Guinea pig polyclonal anti-TIP47 
(Fitzgerald), rabbit polyclonal anti-Sec 13 (Abcam), 
rabbit polyclonal anti-beta COP (Abcam), mouse 
monoclonal anti-Tubulin (Santa Cruz), mouse 
monoclonal anti-Arf1 (Abcam), rabbit polyclonal anti-
Arf4 (Proteintech), rabbit polyclonal anti-Giantin 
(Abcam), and mouse monoclonal anti-GBF1 (BD 
Transduction Laboratories). Rabbit polyclonal and 
mouse polyclonal anti-DENV capsid were obtained in 
our laboratory. For DENV envelope detection, mouse 
monoclonal anti-E antibody E18 was used (57). For 
lipid droplets staining, cells were incubated with 
BODIPY493/503 (Molecular Probes). 
Immunofluorescence assays were performed as 
previously described (8). Briefly, A549 cells were 
seeded into 24-well plates containing glass coverslip. 
Twenty four hours later, the cells were infected with 
DENV-2 using a multiplicity of infection of 10. At 24 
hours post-infection coverslip were collected and the 
cells were fixed with paraformaldehyde 4%, sucrose 
4%, in PBS pH 7.4 at room temperature for 20 
minutes. Alternatively, cells were fixed with methanol 
for 20 minutes at -20°C. PFA fixed cells were then 
permeated with 0.1% Triton X-100 for 4 minutes at 
room temperature.  Images were obtained with a Carl 
Zeiss LSM 5 Pascal confocal microscope. For 
quantification of LD associated capsid, about 200 
cells were scored for each experiment.  Mean and 
standard deviation were indicated in each case. Three 
independent experiments were performed in each 
condition. 
Subcellular fractionation 
For subcellular fractionation Qproteome Cell 
Compartment kit (QIAGEN) was used according 
manufacturer’s protocol. The kit allows sequential 
isolation of proteins associated with the cytosol, 
membranes and nucleus from cell lysates. Different 
extraction buffers were added sequentially to an 
infected cell pellet, and the respective fractions were 
isolated by centrifugation. Each fraction was 
evaluated by Western blot with specific markers: anti-
TIP47, anti-calnexin, and anti-Histone H3 antibodies. 
Additionally, each fraction was evaluated with anti-
capsid antibodies at different times post-infection. 
Brefeldin A and Golgicide A treatments 
Confluent A549 cells were infected with DENV-2 
16681 using a multiplicity of infection of 10. After 1 
hour, cells were washed with PBS and DMEM-F12 
medium supplemented with 10% serum was added. 
At 8 hours post-infection fresh medium with 0, 0.05, 
0.1 or 0,5 g/ml of Brefeldin A (Sigma), or 50µM of 
Golgicide A (Sigma) was added. The medium was 
supplemented with 100 µM of oleic acid (Sigma) 
complexed with BSA (58). For immunofluorescence 
the cells were fixed at 24 hours post-infection.   
Plasmids and transfection 
YFP-tagged GBF1 constructs were kindly provided by 
J. Bonifacino and C. Jackson (59). GFP-Rab1b N121I 
mutant has been previously described (29). For 
expression of heterologous proteins, confluent A549 
cells were infected with DENV-2 and at 4 hours post-
infection transfected with different plasmids using 
Lipofectamine 2000 (Invitrogen), according to 
manufacturer’s protocol. At 24 hours post-infection the 
cells were fixed with paraformaldehyde and 
immunofluorescences were performed. 
RNA interference 
RNA interference experiments were carried out using 
siGENOME ON-TARGET plus SMART pool siRNA 
oligonucleotides (Dharmacon RNA Technologies, 
Lafayette, CO, USA). RNAi were directed to GBF1 
(8729), Sec13 (6396),  COP (1314 and 1315), Arf1 
(375) or Arf4 (378). The control no-related siRNA 
used was directed to Renilla luciferase. At 24 hours 
after seeded in 24-well plates, A549 cells were 
transfected with the corresponding siRNA using 
Oligofectamine (Invitrogen). Briefly, 25 pmol of siRNA 
in 50 µl of Opti-MEM (Invitrogen) were mixed with 2 µl 
of Oligofectamine in 50 µl of Opti-MEM and incubated 
for 20 minutes. The mix was added to a 50% 
confluent A549 cells monolayer and incubated 
overnight. Then, the medium was replaced with 
complete DMEM F12 medium. After 48 hours of 
transfection, except in cases that indicate otherwise, 
cells were infected with DENV-2 and incubated for 24 
hours.   
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Figure 1. Subcellular localization of DENV C in A549 infected cells. A Immunofluorescence of C in 
infected cells using methanol as fixation method. A549 cells were infected with DENV and localization of 
C was analyzed in respect to different markers using antibodies anti-B23 (nucleolus), anti-DENV 
envelope E protein and anti-TIP47 (lipid droplets). Arrows indicate co-localization of C with markers for 
each case. B. Western blots with lysates of infected cells fractionated into cytoplasmic (Cyt), membranes 
(Me), and nuclear (Nu) fractions. The viral protein was detected with anti-C antibodies at 12, 16, and 20 
hours post-infection, as indicated. The samples were immunobloted with anti-histone H3, anti-calnexina 
and anti-TIP47, as markers for each fraction. C. Immunofluorescence of C in infected cells using 
paraformaldehyde as fixation method allows lipid droplet visualization. Lipid droplets were stained with 
BODIPY and localization of viral C and the host TIP47 was determined with specific antibodies as 
indicated in each case. 
Figure 2. Brefeldin A blocks C localization on LDs in DENV infected cells. A. Immunofluorescence 
showing the effect of BFA on C associated to LDs. Specific antibodies against C and TIP47 were used in 
infected cells as indicated on the top. LDs were stained with BODIPY. Representative confocal images 
are shown for each case in the absence or presence of 0.05 µg/ml of BFA. Quantification of the 
percentage of C that co-localizes with TIP47 (mean +/- standard deviation) was performed using ImajeJ 
(JACoP plug-in), Manders’ coefficient is shown. B. Immunofluorescence showing the effect of BFA on C 
accumulation in nucleolus using methanol as fixation method.  Representative confocal images using 
antibodies against C and B23 (marker of nucleolus) are shown in the absence or presence of 0.05 µg/ml 
of BFA. Quantification of the percentage of C that co-localizes with B23 (mean +/- standard deviation) 
was performed using ImajeJ (JACoP plug-in), Manders’ coefficient is shown. C.  Total amount of C in 
cells treated or not with BFA. Cell extracts were used for immunoblots with specific anti-C antibodies. D. 
Effect of different concentrations of BFA on C association to LDs. Confluent A549 infected cells were 
treated at 8 h post-infection with 0, 0.05, 0.1 or 0.5 µg/ml of BFA. At 24 h post-infection cells were 
immunostained with anti-TIP47 and anti-C antibodies and the percentage of cells with C on LDs was 
determined. About 200 cells were scored; bars indicate the standard error of the mean. E. The effect of 
BFA on C association to LDs is reversible. A549 infected cells were treated with 0.1 µg/ml of BFA; then, 
the BFA was removed and cells incubated with fresh media.   Immunofluorescence at 60, 90 and 120 min 
were used to evaluate C and TIP47 on LDs. The percentage of cells with C on LDs is shown for each 
time. About 200 cells were scored in duplicates. Bars indicate the standard error of the mean. F. 
Golgicide A impairs C localization on LDs. Immunofluorescence showing the effect of 50 µM of Golgicide 
A on C association to LDs in A549 cells. Representative confocal images of cells treated or not with the 
drug (Control or GCA) are shown stained with BODIPY for LDs, or labeled with anti-TIP47 and anti-
Capsid as indicated for each case. Right panel, quantification of the percentage of capsid that co-
localizes with TIP47 (mean +/- standard deviation), Manders’ coefficient is shown. 
Figure 3. Golgi integrity is not required for C association to LDs A. Effect of Rab1b dominant negative on 
giantin distribution. On the left, quantification of cells with giantin in Golgi, expressing either the WT or the 
dominant negative (DN) form of Rab1b (N121I), as indicated. On the right, Representative confocal 
images showing the effect of expressing a DN form of GFP-Rab1b (N121I) on the cellular distribution of 
giantin. Arrows indicate cells expressing or not GFP-Rab1b (N121I), labeled with anti-giantin antibodies. 
B. On the left, quantification of cells with C on LDs, expressing either the WT or the DN form of GFP-
Rab1b, as indicated. On the right, representative confocal images showing the effect of expressing the 
DN form of GFP-Rab1b (N121I) on the cellular distribution of the viral C protein. 
Figure 4. COPI but not COPII components are required for C localization on LDs. A. 
Immunofluorescence showing the effect of COPI depletion on C distribution in DENV infected cells. A549 
cells were transfected with non-related siRNA directed to Renilla luciferase (siRNA NR), siRNAs against 
the subunit of COPI (siRNA COP), or siRNAs against the COPII component Sec13 (siRNA Sec13), as 
indicated on the top of each panel. The cells were infected with DENV-2 and immune-stained with anti-
TIP47 as control and anti-C. Representative confocal images are shown. B. Immunoblot analysis showing 
COP and Sec13 depletion. Extracts of A549 cells transfected with siRNA COP (on the left) and siRNA 
Sec13 (on the right), were immunoblotted with specific antibodies. The same membranes were 
immunoblotted with anti-tubulin as a loading control, and antibodies against the viral C protein, as 
indicated on the left of each panel. C. Quantification of the percentage of cells with C on LDs after 
interference with siRNA against COP, Sec13 or a nonrelated siRNA control (NR). In each case, 200 
cells were scored for the presence of C on LDs in three independent experiments. The bars indicate the 
standard error of the mean. D. Redundancy of Arf1 and Arf4 for C association to LDs in DENV infected 
cells. Immunoblot showing cells treated with siRNA directed to Arf1, Arf4, Arf1+Arf4, or control (NR). 
Antibodies anti-Arf1, anti-Arf4 or anti-tubulin were used as indicated on each case. E. Effect of Arfs 
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depletion on C accumulation on LDs. Quantification of the percentage of cells with C on LDs in cells 
interfered with a NR siRNA or siRNAs against Arf1, Arf4 or both. In each case, 200 cells were scored for 
the presence of C on LDs in three independent experiments. The bars indicate standard error of the 
mean.   
Figure 5. GBF1 function is necessary for C accumulation on LDs. A. On the left, representative confocal 
images showing the effect of expressing YFP-GBF1 WT or E794K (dominant negative, DN) on the 
cellular distribution of C. A549 cells were infected with DENV-2 and 4h later transfected with the GBF1 
expressing plasmids. Immunofluorescence was performed 24 h post-infection using anti-capsid 
antibodies. On the right, the amount of YFP positive cells with C on LDs were scored and shown as 
percentage of cells with C on LDs. About 100 cells were scored in each case in duplicates. Errors bars 
indicate the standard error of the mean. B. Effect of GBF1 depletion on C accumulation on LDs. On the 
left, immunoblot showing GBF1 depletion. Extracts of A549 cells transfected with siRNAs for GBF1 or NR 
siRNAs were immunoblotted with anti-GBF1 antibodies. The same membrane was immunoblotted with 
anti-tubulin as a loading control, as indicated. On the left, representative confocal image showing A549 
cells depleted or not of GBF1 using anti-GBF1 antibodies (green) and indicating the distribution of the 
viral C in infected cells by anti-C antibodies (red).  
Figure 6. BFA-resistant GBF1 reverts the effect of BFA on C localization. A. Representative confocal 
images showing the effect of expressing YFP-GBF1- M832L (BFA resistant) on the subcellular 
distribution of C in the presence and absence of BFA. A549 cells were infected with DENV-2 and 4h later 
transfected with the GBF1 expressing plasmids. Immunofluorescence was performed 24 h post-infection 
using anti-C antibodies. B. Percentage of C on LDs of cells expressing  YFP control, YFP- GBF1 WT, or  
YFP-GBF1- M832L,  in BFA-treated or non-treated cells, as indicated for each case. About 100 cells 
expressing YFP were scored for the presence of C on LDs in two independent experiments. Bars indicate 
standard error of the mean. 
 
 
 
 
 
 
 
 
 
